We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Turns out, after GlaxoSmithKline walked away from a chance to scoop up Pfizer’s consumer health business in March, it got another opportunity to team up on a deal.
There has been a raft of changes at senior levels of GSK since Emma Walmsley took over the role from Andrew Witty, with the latest seeing its R&D head set to leave to become the UK government’s Chief Scientific Adviser.
Emma Walmsley will succeed Andrew Witty as GSK CEO, when he retires today, Friday 31 March 2017. She will be the first female CEO of a major global pharmaceuticals company.